Protagonist Therapeutics Inc. (PTGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX Summary
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal
Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA approval and rusfertide's Priority Review position PTGX for milestone payments, high-margin royalties, and a capital-light revenue model. PTGX maintains a strong balance sheet with $620M+ cash, a funding runway through 2028, and episodic profitability, reducing financing risk.
Protagonist Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 86 | $4,234.32 | $11,715.82 | $7,481.5 | 176.69% |
| ML Marc Larkins Johnson & Johnson | 2.45M | $43.4M | $332.62M | $289.22M | 666.42% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 19 | $1,966.48 | $2,582.67 | $616.19 | 31.33% |
 Farallon Capital Farallon Capital Management LLC | 6.35M | $137.43M | $866.7M | $729.27M | 530.66% |
| BG Bart Gancher Intech Investment Management LLC | 13,006 | $592,597.25 | $1.77M | $1.18M | 199.01% |
Protagonist Therapeutics Inc. (PTGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protagonist Therapeutics Inc. ever had a stock split?
Protagonist Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dinesh V. Patel CEO | NASDAQ (NMS) Exchange | 74366E102 CUSIP |
| US Country | 132 Employees | - Last Dividend | - Last Split | 11 Aug 2016 IPO Date |
Overview
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on the development of peptide-based drugs to address unmet medical needs in the areas of hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. Incorporated in 2006, the company has dedicated its research and development efforts to create innovative treatments, leveraging its expertise in peptide technology. Headquartered in Newark, California, Protagonist Therapeutics stands at the forefront of drug development, working in collaboration with industry leaders such as Takeda and JNJ Innovative Medicines to bring new therapies to market.
Products and Services
List of key developmental drugs and collaborations:
- Rusfertide (PTG-300): An injectable hepcidin mimetic designed for the treatment of polycythemia vera and other blood disorders. Rusfertide has completed phase 2 clinical trials, showing promise as a novel therapeutic option. This development is part of a licensing and commercialization agreement with Takeda, aiming to make a significant impact on patients' lives by addressing the unmet needs in hematology.
- JNJ-2113: This orally delivered investigational drug is designed to block biological pathways involved in moderate-to-severe plaque psoriasis. Having completed phase 2b clinical trials, JNJ-2113 is developed in collaboration with JNJ Innovative Medicines. The partnership focuses on co-developing this Interleukin-23 receptor antagonist compound, which represents a novel approach to treating inflammatory diseases.
- PN-943: An orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, PN-943 has completed a phase 2 clinical trial for patients with moderate to severe ulcerative colitis. This drug aims to offer a targeted therapeutic approach, reducing the systemic side effects often associated with current treatments for this chronic and debilitating condition.
